Delving into the Latest Updates on Jiamusi with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Neoplasms

mRNA

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

mRNA	1

Top 5 Target	Count

endothelin 1	1

Nanozymes with biological enzyme activity show great promise in biochemical analysis and medicine, yet single-activity nanozymes were limited by low catalytic efficiency and strict catalytic environment requirements. Consequently, the development of nanozymes with multiple enzyme activities presents a significant challenge. In the work, a vanadium-capped polyoxometalates (POMs)-encapsulating metal-organic framework (MOF), [Cu₁₂(Trz)₈Cl][PMo₁₂O₄₀(VO)₂], was synthesized via hydrothermal synthesis, which shows multiple enzyme activities concluding oxidase (OXD), peroxidase (POD) and catalase (CAT) activities. In the catalytic procedure, a fraction of H₂O₂ generated by the OXD is further subjected to the POD catalytic reaction and the remaining portion is transformed into O₂ through the CAT activity, in turn, supplies the driving force for the OXD-like catalytic process. This cascade reaction, in conjunction with the transformation between Cu²⁺ and Cu⁺ within the material, engenders a structure analogous to an interlocking "gear", which augments the catalytic efficacy as well as the adaptability to intricate environmental conditions of the [Cu₁₂(Trz)₈Cl][PMo₁₂O₄₀(VO)₂] enzyme. By capitalizing on this high catalytic efficiency, the rapid quantitative detection of glutathione (GSH) was established with the calculated limit of detection (LOD) 0.062 μM in the range of 5-60 μM. Surprisingly, the multi-enzymatic [Cu₁₂(Trz)₈Cl][PMo₁₂O₄₀(VO)₂] can concurrently enhance the generation of reactive oxygen species (ROS) and the depletion of GSH in the tumor microenvironment (TME), thereby inducing tumor cell apoptosis. This research holds promising application prospects in the fields of biotechnology, clinical diagnosis, and tumor therapy.

01 Aug 2025·Journal of Inorganic Biochemistry

An efficient circularly polarized luminescence probe base on anthryl-modified Eu(III)-helicates for the detection and imaging singlet oxygen in living cells

Article

Author: Yin, Sen ; Zhou, Yanyan ; Zhang, Xiumei ; Huang, Wenru ; Wang, Xinglu ; Yan, Pengfei ; Gao, Ting ; Li, Hongfeng

Singlet oxygen (¹O₂) is the main active ingredient in photodynamic therapy (PDT). However, an excess ¹O₂ can cause unnecessary toxicity. Therefore, it is of great importance to develop reliable and sensitive methods or probes for detecting ¹O₂ in biological systems. In this study, a pair of anthryl-modified Eu(III) binaphthol-bis-β-diketones helicates, (NEt₄)₂[Eu₂(L^R/S)₄] are designed, synthesized and characterized. Initially, the complexes display faint luminescence. Upon reacting with ¹O₂ to create endoperoxides of the anthracene framework, the long-lived luminescence of the Eu(III) complexes is activated. Notably, the high luminescence dissymmetry factor, g_lum of the ⁵D₀ → ⁷F₁ transition (595 nm) shows an obvious increase from -1.21 to -1.29 before and after oxidation. The complex exhibits a highly selective luminescent response to the ¹O₂ generated by 5-aminolevulinic acid (ALA) loaded 4 T1 cells during photodynamic processes. To the best of we knowledge, this is the first example of ¹O₂ detection based on circularly polarized luminescence (CPL) probe. The design of the lanthanide CPL probe provides a practical way for the sensitive detection of ¹O₂ in the future.

100 Deals associated with Jiamusi

Login to view more data

100 Translational Medicine associated with Jiamusi

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Login to view more data